Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Just saw this exchange between Musk and Cuban on X that's worth paying attention to. Musk basically asked a straightforward question — why can't Americans get real value for what they're spending on healthcare? — and Cuban didn't hold back with his response.
What's interesting is that Cuban didn't blame the government or some abstract "system." Instead, he went after the actual players making money off the current setup: the pharmacy benefit managers and the contracts companies sign with them. And honestly, once you see how these deals work, it's hard to unsee.
He broke down seven specific ways the system is rigged against both employers and patients. The one that stood out to me is that companies literally don't own their own claims data. They're paying the bills but can't even see where the money's going. That's insane. Then there's the part about PBMs deciding which drugs employees can access instead of the companies actually footing the bill. They'll push expensive medications over cheaper alternatives because that's where the rebates are.
Cuban called out "specialty drugs" as basically a pricing scam — drugs that aren't actually special, just marked up to be expensive. And the way rebates are structured? The sickest employees end up paying the most. Independent pharmacies get squeezed out because PBMs reimburse them below cost. CEOs can't negotiate directly with manufacturers, and half these contracts have NDAs that literally prevent them from talking about the deal publicly.
But here's where it gets interesting — Cuban isn't just complaining. He's actually building something different with Cost Plus Drugs, cutting out the middlemen entirely and selling direct to consumers. No hidden fees, full transparency on pricing.
The whole thing feels like a potential inflection point. If this model actually scales, it could force some real change in how the industry operates. Definitely worth watching how this plays out over the next year.